Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Reker, S; Meier, A; Holten-Andersen, L; Svane, IM; Becker, JC; Straten, PT; Andersen, MH.
Identification of novel survivin-derived CTL epitopes
CANCER BIOL THER. 2004; 3(2): 173-179. Doi: 10.4161/cbt.3.2.611 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Becker Jürgen Christian
Altmetrics:

Dimensions Citations:
Plum Analytics:


Scite (citation analytics):

Abstract:
The identification of tumor antigens, which are essential for the survival of tumor cells is a new avenue to prevent antigen loss variants emerging due to immunoselection, particularly during immune therapy. In the search for such immunogenic tumor antigens, we recently identified spontaneous cytotoxic lymphocyte (CTL) responses against the inhibitor of apoptosis protein survivin. Thus, we identified two HLA-A2-restricted, survivin-derived CTL epitopes, which both were targets for spontaneous CTL responses in melanoma, breast cancer, and CLL. Here, we extend these data and describe the characterization of novel HLA-Al-, HLA-A2-, HLA-A3-, and HLA-A11-restricted survivin epitopes on the basis of spontaneous CTL responses in cancer patients. These epitopes significantly increase the number of patients eligible for immunotherapy based on survivin derived peptides. Additionally, the collective targeting of several restriction elements is likely to decrease the risk of immune escape by HLA-allele loss.

Find related publications in this database (Keywords)
tumor antigens
survivin
HLA-restriction
CTL
immunotherapy
cancer vaccine
© Med Uni Graz Impressum